Circulating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic Interest

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Mondet, Julie ^a,b   Hussein, Kais ^c   Mossuz, Pascal ^a,b  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b UNIV GRENOBLE ALPES   (France)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHEMOKINE; CYTOKINE; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 7; INTERLEUKIN 8; JANUS KINASE 1; JANUS KINASE 2 INHIBITOR; JANUS KINASE INHIBITOR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN; BIOLOGICAL MARKER; JANUS KINASE;

ACUTE MYELOBLASTIC LEUKEMIA; ANGIOGENESIS; BLOOD CELL COUNT; CANCER PROGNOSIS; CARDIOVASCULAR RISK; CYTOKINE PRODUCTION; DISEASE COURSE; ERYTHROPOIESIS; GENE FREQUENCY; GRANULOCYTE; HUMAN; INFLAMMATION; MEGAKARYOCYTE; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; PATHOGENESIS; PHILADELPHIA CHROMOSOME NEGATIVE CELL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; THROMBOCYTHEMIA; THROMBOSIS; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; GENE EXPRESSION REGULATION; METABOLISM; MYELOPROLIFERATIVE DISORDERS; PHENOTYPE; PHILADELPHIA 1 CHROMOSOME; PRIMARY MYELOFIBROSIS; PROGNOSIS;

ANIMALS; BIOMARKERS; CYTOKINES; DISEASE PROGRESSION; GENE EXPRESSION REGULATION; GRANULOCYTES; HUMANS; INFLAMMATION; JANUS KINASES; MYELOPROLIFERATIVE DISORDERS; PHENOTYPE; PHILADELPHIA CHROMOSOME; PRIMARY MYELOFIBROSIS; PROGNOSIS;

EID: 84945262904     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/670580     Document Type: Review

References (59)

1. M. Majka, A. Janowska-Wieczorek, J. Ratajczak et al., "Numerous growth factors, cytokines, and chemokines are secreted by human CD34+ cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner," Blood, vol. 97, no. 10, pp. 3075-3085, 2001.
2. J.W. Vardiman, J. Thiele, D. A. Arber et al., "The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes," Blood, vol. 114, no. 5, pp. 937-951, 2009.
3. S. Verstovsek, H. Kantarjian, R. A. Mesa et al., "Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis," The New England Journal of Medicine, vol. 363, no. 12, pp. 1117-1127, 2010.
4. S. Verstovsek,F.Passamonti, A. Rambaldi et al., "Aphase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea," Cancer, vol. 120, no. 4, pp. 513-520, 2014.
5. C. W. Hollen, J. Henthorn, J. A. Koziol, and S. A. Burstein, "Elevated serum interleukin-6 levels in patients with reactive thrombocytosis," British Journal of Haematology, vol. 79, no. 2, pp. 286-290, 1991.
6. K. E. Panteli, E. C. Hatzimichael, P. K. Bouranta et al., "Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases," British Journal ofHaematology, vol. 130, no. 5,pp. 709-715, 2005.
7. T. Kawatani, A. Endo, F. Tajima, S. Ooi, and H. Kawasaki, "Clinical significance of serum soluble interleukin-2 receptor in chronic myeloproliferative disorders," International Journal of Hematology, vol. 65, no. 2, pp. 123-128, 1997.
8. K. L. Bourantas, E. C. Hatzimichael, A. C. Makis et al., "Serum beta-2-microglobulin, TNF-and interleukins in myeloproliferative disorders," European Journal of Haematology, vol. 63, no. 1, pp. 19-25, 1999.
9. S. Hermouet, A. Godard, D. Pineau et al., "Abnormal production of interleukin (IL)-11 and IL-8 in polycythaemia vera," Cytokine, vol. 20, no. 4, pp. 178-183, 2002.
10. M. Griesshammer, A. Hornkohl, J. L. Nichol et al., "High levels of thrombopoietin in sera of patients with essential thrombocythemia: cause or consequence of abnormal platelet production" Annals of Hematology, vol. 77, no. 5, pp. 211-215, 1998.
11. S. Karakus, O. I. Ozcebe, I. C. Haznedaroglu et al., "Circulating thrombopoietin in clonal versus reactive thrombocytosis," Hematology, vol. 7, pp. 9-12, 2002.
12. P. Mossuz, F. Girodon, M. Donnard et al., "Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis," Haematologica, vol. 89, no. 10, pp. 1194-1279, 2004.
13. A. Tefferi, R. Vaidya, D. Caramazza, C. Finke, T. Lasho, and A. Pardanani, "Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primarymyelofibrosis: a comprehensive cytokine profiling study," Journal of Clinical Oncology, vol. 29, no. 10, pp. 1356-1363, 2011.
14. R. Vaidya, N. Gangat, T. Jimma et al., "Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis," American Journal of Hematology, vol. 87, no. 11, pp. 1003-1005, 2012.
15. E. Pourcelot, C. Trocme, J.Mondet, S. Bailly,B.Toussaint, andP. Mossuz, "Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications," Experimental Hematology, vol. 42, no. 5, pp. 360-368, 2014.
16. S. Gangemi, A. Allegra, E. Pace et al., "Evaluation of interleukin-23 plasma levels in patients with polycythemia vera and essential thrombocythemia," Cellular Immunology, vol. 278, no. 1-2, pp. 91-94, 2012.
17. G. V. Shurin, Z. R. Yurkovetsky, G. S. Chatta, I. L. Tourkova, M. R. Shurin, and A. E. Lokshin, "Dynamic alteration of soluble serum biomarkers in healthy aging," Cytokine, vol. 39, no. 2, pp. 123-129, 2007.
18. T. Fulop, A. Larbi, N. Douziech, I. Levesque, A. Varin, and G. Herbein, "Cytokine receptor signalling and aging," Mechanisms of Ageing and Development, vol. 127, no. 6, pp. 526-537, 2006.
19. V. Sarrazy, F. Billet, L. Micallef, B. Coulomb, and A. Desmoulière, "Mechanisms of pathological scarring: role of myofibroblasts and current developments," Wound Repair and Regeneration, vol. 19, no. 1, pp. S10-S15, 2011.
20. S. H. Swerdlow, E. Campo, H. L. Harris et al., WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, France, 2008.
21. B. S. Wilkins, W. N. Erber, D. Bareford et al., "Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes," Blood, vol. 111, no. 1, pp. 60-70, 2008.
22. T. Buhr, K. Hebeda, V. Kaloutsi, A. Porwit, J. Van der Walt, and H. Kreipe, "European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis," Haematologica, vol. 97, no. 3, pp. 360-365, 2012.
23. J. Thiele, A. Orazi, H. M. Kvasnicka et al., "European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 2012;97(3):360-5-comment," Haematologica, vol. 97, no. 3, pp. e5-e6, 2012.
24. W. Dameshek, "Some speculations on the myeloproliferative syndromes," Blood, vol. 6, no. 4, pp. 372-375, 1951.
25. C. James, V. Ugo, J.-P. Le Couédic et al., "A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera," Nature, vol. 434, no. 7037, pp. 1144-1148, 2005.
26. H. Kreipe, G. Büsche, O. Bock, and K. Hussein, "Myelofibrosis: molecular and cell biological aspects," Fibrogenesis & Tissue Repair, vol. 5, article S21, 2012.
27. K.Hussein, "Pathobiology of the microRNA system," Pathologe, vol. 33, no. 1, pp. 70-78, 2012.
28. M. Muth, G. Büsche, O. Bock, K. Hussein, and H. Kreipe, "Aberrant proplatelet formation in chronic myeloproliferative neoplasms," Leukemia Research, vol. 34, no. 11, pp. 1424-1429, 2010.
29. O. Bock, G. Loch, G. Büsche, R. vonWasielewski, J. Schlué, and H. Kreipe, "Aberrant expression of platelet-derived growth factor (PDGF) and PD6F receptor-is associated with advanced bone marrow fibrosis in idiopathic myelofibrosis," Haematologica, vol. 90, no. 1, pp. 133-134, 2005.
30. O. Bock, G. Loch, U. Schade, R. von Wasielewski, J. Schlué, and H. Kreipe, "Aberrant expression of transforming growth factor-1 (TGF-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders," Journal of Pathology, vol. 205, no. 5, pp. 548-557, 2005.
31. O. Bock,M.Muth, K.Theophile et al., "Identification of newtarget molecules PTK2, TGFBR2 and CD9 overexpressed during advanced bone marrow remodelling in primary myelofibrosis," British Journal ofHaematology, vol. 146, no. 5,pp. 510-520, 2009.
32. K. Hussein, G. Büsche, J. Schlue, U. Lehmann, and H. Kreipe, "Myeloproliferative neoplasms: histopathological and molecular pathological diagnosis," Pathologe, vol. 33, no. 6, pp. 508-517, 2012.
33. M.Muth, B.M. Engelhardt,N.Kröger et al., "Thrombospondin-1 (TSP-1) in primary myelofibrosis (PMF)-a megakaryocytederived biomarker which largely discriminates PMF from essential thrombocythemia," Annals of Hematology, vol. 90, no. 1, pp. 33-40, 2011.
34. O. Bock, J. Neuse, K. Hussein et al., "Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status," The American Journal of Pathology, vol. 169, no. 2, pp. 471-481, 2006.
35. H. C. Chong, C. K. Tan, R.-L. Huang, and N. S. Tan, "Matricellular proteins: a sticky affair with cancers," Journal of Oncology, vol. 2012, Article ID 351089, 17 pages, 2012.
36. N. T. Fernando, M. Koch, C. Rothrock et al., "Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors," Clinical Cancer Research, vol. 14, no. 5, pp. 1529-1539, 2008.
37. E. Boveri, F. Passamonti, E. Rumi et al., "Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations," British Journal of Haematology, vol. 140, no. 2, pp. 162-168, 2008.
38. M. Medinger, R. Skoda, A. Gratwohl et al., "Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status," British Journal of Haematology, vol. 146, no. 2, pp. 150-157, 2009.
39. U.Gianelli, C. Vener, P. R. Raviele et al., "VEGF expression correlates with microvessel density in Philadelphia chromosomenegative chronic myeloproliferative disorders," American Journal of Clinical Pathology, vol. 128, no. 6, pp. 966-973, 2007.
40. S.M. Kornblau, D. McCue, N. Singh, W. Chen, Z. Estrov, and K. R. Coombes, "Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acutemyelogenous leukemia andmyelodysplasia," Blood, vol. 116, no. 20, pp. 4251-4261, 2010.
41. K. Nakase, K. Kita, T. Kyo, K. Tsuji, and N. Katayama, "High serum levels of soluble interleukin-2 receptor in acutemyeloid leukemia: correlation with poor prognosis and CD4 expression on blast cells," Cancer Epidemiology, vol. 36, no. 5, pp. e306-e309, 2012.
42. Q.-T. Le,R. Fisher, K. S. Oliner et al., "Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancer," Clinical Cancer Research, vol. 18, no. 6, pp. 1798-1807, 2012.
43. P. H. Reitsma and F. R. Rosendaal, "Activation of innate immunity in patients with venous thrombosis: the Leiden Thrombophilia Study," Journal of Thrombosis and Haemostasis, vol. 2, no. 4, pp. 619-622, 2004.
44. T. Barbui, A. Carobbio, G. Finazzi et al., "Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3," Haematologica, vol. 96, no. 2, pp. 315-318, 2011.
45. M. Boissinot, C. Cleyrat, M. Vilaine, Y. Jacques, I. Corre, and S. Hermouet, "Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F," Oncogene, vol. 30,no. 8, pp. 990-1001, 2011.
46. A. Tefferi and A. Pardanani, "Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis," Mayo Clinic Proceedings, vol. 86, no. 12, pp. 1188-1191, 2011.
47. A. Quintás-Cardama, K. Vaddi, P. Liu et al., "Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment ofmyeloproliferative neoplasms," Blood, vol. 115, no. 15, pp. 3109-3117, 2010.
48. C. Keohane, S. Kordasti, T. Seidl et al., "JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells," British Journal of Haematology, 2015.
49. M. Kleppe, M. Kwak, P. Koppikar et al., "JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response," Cancer Discovery, vol. 5, no. 3, pp. 316-331, 2015.
50. R. Zeiser, A. Burchert, C. Lengerke et al., "Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multi-center survey," Leukemia, 2015.
51. M. Gadina, "Janus kinases: an ideal target for the treatment of autoimmune diseases," Journal of Investigative Dermatology Symposium Proceedings, vol. 16, no. 1, pp. S70-S72, 2013.
52. L. Gu, P. Talati, P. Vogiatzi et al., "Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation," Molecular Cancer Therapeutics, vol. 13, no. 5, pp. 1246-1258, 2014.
53. Y. Liu, A. T.Holdbrooks, P.De Sarno et al., "Therapeutic efficacy of suppressing the JAK/STAT pathway in multiple models of experimental autoimmune encephalomyelitis," The Journal of Immunology, vol. 192, no. 1, pp. 59-72, 2014.
54. K. L. Stump, L. D. Lu, P. Dobrzanski et al., "A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis," Arthritis Research andTherapy, vol. 13, no. 2, article R68, 2011.
55. A. Tefferi, "JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths," Blood, vol. 119, no. 12, pp. 2721-2730, 2012.
56. A. Pardanani, J. R. Gotlib, C. Jamieson et al., "Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis," Journal of Clinical Oncology, vol. 29, no. 7, pp. 789-796, 2011.
57. F. P. S. Santos, H. M. Kantarjian, N. Jain et al., "Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis," Blood, vol. 115, no. 6, pp. 1131-1136, 2010.
58. J. W. Tyner, T. G. Bumm, J. Deininger et al., "CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms," Blood, vol. 115, no. 25, pp. 5232-5240, 2010.
59. L. Belver and A. A. Ferrando, "Aberrant cytokine production by nonmalignant cells in the pathogenesis ofmyeloproliferative tumors and response to JAK inhibitor therapies," Cancer Discovery, vol. 5, no. 3, pp. 234-236, 2015.